Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108:2435–2447. https://doi.org/10.1083/jcb.108.6.2435

Article  CAS  PubMed  Google Scholar 

Bianchini F, Portioli E, Ferlenghi F et al (2019) Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. Cancer Lett 446:25–37. https://doi.org/10.1016/j.canlet.2018.12.021

Article  CAS  PubMed  Google Scholar 

Blaquier JB, Ortiz-Cuaran S, Ricciuti B et al (2023) Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res 29:3579–3591. https://doi.org/10.1158/1078-0432.CCR-22-1912

Article  CAS  PubMed  Google Scholar 

Chen XF, Zhang HJ, Wang HB et al (2012) Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep 39:3549–3556. https://doi.org/10.1007/s11033-011-1128-0

Article  CAS  PubMed  Google Scholar 

Chen Q, Jia G, Zhang X et al (2024) Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Front Immunol 14:1332057. https://doi.org/10.3389/fimmu.2023.1332057. Erratum in: Front Immunol 15:1376045 https://doi.org/10.3389/fimmu.2024.1376045

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55. https://doi.org/10.1016/0065-2571(84)90007-4

Article  CAS  PubMed  Google Scholar 

Drabsch Y, ten Dijke P (2012) TGF-β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31:553–568. https://doi.org/10.1007/s10555-012-9375-7

Article  CAS  PubMed  Google Scholar 

Falcioni R, Cimino L, Gentileschi MP, D’Agnano I, Zupi G, Kennel SJ, Sacchi A (1994) Expression of Β1, Β3, Β4, and Β5 integrins by human lung carcinoma cells of different histotypes. Exp Cell Res 210:113–122. https://doi.org/10.1006/excr.1994.1017

Article  CAS  PubMed  Google Scholar 

Fu M, Zhao J, Zhang L et al (2024) Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade. Cancer Cell 42:1882–1897e7. https://doi.org/10.1016/j.ccell.2024.09.012

Article  CAS  PubMed  Google Scholar 

Gallant JN, Sheehan JH, Shaver TM et al (2015) EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov 5:1155–1163. https://doi.org/10.1158/2159-8290.CD-15-0654

Article  CAS  PubMed  PubMed Central  Google Scholar 

He J, Huang Z, Han L, Gong Y, Xie C (2021) Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol 59:90. https://doi.org/10.3892/ijo.2021.5270

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471. https://doi.org/10.1038/37284

Article  CAS  PubMed  Google Scholar 

Huang L, Fu L (2015) Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 5:390–401. https://doi.org/10.1016/j.apsb.2015.07.001

Article  PubMed  PubMed Central  Google Scholar 

Jeong J, Kim J (2021) Cyclic RGD pentapeptide cilengitide enhances efficacy of gefitinib on TGF-β1-induced epithelial-to-mesenchymal transition and invasion in human non-small cell lung cancer cells. Front Pharmacol 12:639095. https://doi.org/10.3389/fphar.2021.639095

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeong J, Kim J (2022) Combination effect of cilengitide with erlotinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. Int J Mol Sci 23:3423. https://doi.org/10.3390/ijms23073423

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ju L, Zhou C (2013) Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int 13(1):15. https://doi.org/10.1186/1475-2867-13-15

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ju L, Zhou C, Li W, Yan L (2010) Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 111(6):1565–1574. https://doi.org/10.1002/jcb.22888

Article  CAS  PubMed  Google Scholar 

Kobayashi Y, Azuma K, Nagai H et al (2017) Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to Afatinib in lung cancer. Mol Cancer Ther 16:357–364. https://doi.org/10.1158/1535-7163.MCT-16-0407

Article  CAS  PubMed  Google Scholar 

Li CM, Haratipour P, Lingeman RG et al (2021) Novel peptide therapeutic approaches for cancer treatment. Cells 10:2908. https://doi.org/10.3390/cells10112908

Article  CAS  PubMed  PubMed Central  Google Scholar 

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta delta C(T)), method. Methods 25:402–408. https://doi.org/10.1006/meth.2001.1262

Article  CAS  PubMed  Google Scholar 

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388. https://doi.org/10.1056/NEJMoa0909530

Article  CAS  PubMed  Google Scholar 

Mas-Moruno C, Rechenmacher F, Kessler H (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10:753–768. https://doi.org/10.2174/187152010794728639

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massagué J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19:2783–2810. https://doi.org/10.1101/gad.1350705

Article  CAS  PubMed  Google Scholar 

Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128. https://doi.org/10.1016/S1470-2045(09)70364-X

Article  CAS  PubMed  Google Scholar 

Mittal V (2018) Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol 13:395–412. https://doi.org/10.1146/annurev-pathol-020117-043854

Article  CAS  PubMed  Google Scholar 

Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M, Papotti M, Turco E, Defilippi P (2011) β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30(39):4087–4096. https://doi.org/10.1038/onc.2011.107

Article  CAS  PubMed  Google Scholar 

Oh SY, Lee YW, Lee EJ et al (2023) Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res 29:221–232. https://doi.org/10.1158/1078-0432.CCR-22-2180

Article  CAS  PubMed  Google Scholar 

Park KY, Kim J (2020) Cyclic pentapeptide cRGDfK enhances the inhibitory effect of Sunitinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells. PLoS ONE 15:e0232917. https://doi.org/10.1371/journal.pone.0232917

Article  CAS